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Abstract
Background: Impaired mobility and falls are clinically important complications of Parkinson’s disease (PD) and a
major detractor from quality of life for which there are limited therapies. Pathological, neuroimaging and clinical
evidence suggest that degeneration of cholinergic systems may contribute to impairments of balance and gait in
PD. The proposed trial will examine the effects of augmentation of the cholinergic system on balance and gait.
Design: The study is a single-site, proof of concept, randomized, double-blind, cross-over trial in patients with PD. Each
treatment period will be 6 weeks with a 6-week washout between treatments for a total of 18 weeks for each subject.
Donepezil in 2.5 mg capsules or identical appearing placebo capsules will be increased from two per day (5 mg) to four
capsules (10 mg) after 3 weeks, if tolerated. Subjects will have idiopathic Parkinson’s disease, Hoehn and Yahr stages 2 to
4. We anticipate recruiting up to 100 subjects for screening to have 54 enrolled and 44 subjects complete both phases
of treatment. Dropouts will be replaced. As this is a crossover trial, all subjects will be exposed to both donepezil and to
placebo. The primary outcome measures will be the root mean square of the mediolateral sway when standing and the
variability of the stride duration when walking for two minutes. Secondary outcomes will be the computerized Attention
Network Test to examine three domains of attention and the Short-latency Afferent Inhibition (SAI), a physiological
marker obtained with transcranial magnetic stimulation as a putative marker of cholinergic activity.
Discussion: The results of this study will be the most direct test of the hypothesized role of cholinergic neurotransmission
in gait and balance. The study is exploratory because we do not know whether donepezil will affect gait, balance or
attention, nor which measures of gait, balance or attention will be sensitive to drug manipulation. We hypothesize that
change in cholinergic activity, as measured with SAI, will predict the relative effectiveness of donepezil on gait and
balance. Our immediate goal is to determine the potential utility of cholinergic manipulation as a strategy for preventing
or treating balance and gait dysfunction in PD. The findings of this trial are intended to lead to more sharply focused
questions about the role of cholinergic neurotransmission in balance and gait and eventually to Phase II B trials to
determine clinical utility of cholinergic manipulation to prevent falls and improve mobility.
Trial registration: This trial is registered at clinical trials.gov (NCT02206620).
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Background
Gait and balance problems occur throughout the course
of Parkinson’s disease (PD), appearing within three years
of diagnosis [1–3]. In PD, falls result in injuries [4],
mortality, death, fear of falling [5] and decreased quality
of life [6]. Although levodopa improves some gait pa-
rameters [7] levodopa does not improve, and may
worsen, several types of balance control [8]. For ex-
ample, postural sway area and sway velocity during quiet
stance increase with levodopa in patients with moderate
to severe PD [8]. In addition, the size of automatic
postural responses to external perturbations decrease
with levodopa, which could lead to falls from poor
recovery from a slip or trip [9]. In general, as the
disease progresses, levodopa is less efficacious for bal-
ance and it is assumed that non-dopaminergic sys-
tems are impaired later in the disease course [10].
* Correspondence: mancinim@ohsu.edu
1Parkinson Center of Oregon, Department of Neurology, Oregon Health &
Science University, 3181 S.W. Sam Jackson Park Rd., Portland, OR 97239-3098,
USA
Full list of author information is available at the end of the article
© 2015 Mancini et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Mancini et al. BMC Neurology  (2015) 15:264 
DOI 10.1186/s12883-015-0523-x
Deep Brain Stimulation (DBS) also is generally not ef-
fective for reducing falls [11].
Although the dopaminergic system is preferentially
affected in PD, there are also changes in the basal
forebrain cholinergic complex that provides choliner-
gic innervations of the cortex. In addition, the pedun-
culopontine nucleus (PPN), part of the midbrain
locomotor region (MLR), has a prominent cholinergic
projection to the thalamus and it degenerates in PD
[12]. PET imaging with [11C]PMP, a substrate for
acetylcholinesterase, identifies the integrity of cholin-
ergic innervation. Loss of cortical cholinergic markers
in PD representing degeneration of the basal forebrain
nuclei is associated with slower gait [13] and impair-
ments in working memory, attention and executive
function [14]. Loss of thalamic [11C]PMP, represent-
ing loss of PPN cholinergic innervation of the thal-
amus, is related to falls in PD [15]. In contrast, the
extent of dopaminergic denervation of the striatum
evaluated by PET imaging was not correlated with
falls [15]. Finally, neurotoxin lesioning of the cholin-
ergic neurons of the PPN induced gait and postural
abnormalities in monkeys [16].
The most direct test of the role of cholinergic systems
in balance and gait to date are three small clinical trials
[17–19]. In two randomized, double-blind, crossover
clinical trial of a cholinesterase inhibitor, donepezil, our
group found that donepezil reduced falls in patients with
PD [17] and decreased mean sway velocity in the
Sensory Organization Test [19]. An open trial with an-
other cholinesterase inhibitor, galantamine, also reported
decreases in falls and freezing of gait (FoG) [18]. But
these small clinical trials are not conclusive.
The effects of manipulation of the cholinergic system
could be mediated by at least two general mechanisms, al-
tering attention via effects on cortical and subcortical cho-
linergic systems or altering balance and gait circuitry via
effects on brainstem locomotor cholinergic circuits. In
addition to balance and gait measures, short-latency affer-
ent inhibition (SAI), a physiological index of central cho-
linergic function (ref) will be measured to determine if the
deficits in balance and gait correlate with abnormalities of
the SAI and if SAI is altered by donepezil as a measure of
drug efficacy. Moreover, the attention network test (ANT)
will be administered to determine if changes in gait and
balance are mediated by changes in attention. This study
will be the most direct test of the role of cholinergic sys-
tems in gait and balance. We hypothesized that measures
of gait and balance will improve in response to cholinergic
augmentation with a cholinesterase inhibitor, donepezil.
Methods/Design
The study is a single-site, proof of concept, randomized,
double-blind, cross-over trial in patients with PD. Each
treatment period will be 6 weeks with a 6-week washout
between treatments for a total of 18 weeks for each sub-
ject. See Fig. 1 for protocol details.
Participants
We anticipate recruiting up to 100 subjects for screening
to have 54 enroll and 44 complete both phases of treat-
ment. Dropouts will be replaced. As this is a crossover
trial, all subjects will be exposed to donepezil and to pla-
cebo. Subjects will be 30 years or older, of either sex and
any racial or ethnic origin. Women who are capable of
child bearing must employ birth control. Pregnant
women are not eligible to participate. The subjects will
have idiopathic Parkinson’s disease as determined from
history and exam and lack of history or physical findings
that would suggest another diagnosis or a parkinsonism-
plus syndrome.
Subjects may be Hoehn and Yahr stages II to IV.
Subjects must be able to stand unassisted for a minute
and to walk continuously for 2 min without assistance
or assistive devices. The subjects must have a Montreal
Cognitive Assessment (MOCA) of 23 or above and be
judged to be able to appreciate the purpose of the re-
search, give informed consent to participate, be able to
cooperate with the testing and be compliant with taking
the experimental medications.
Exclusion criteria include: significant tremor which
would interfere with recording balance and walking;
other factors affecting gait such as musculoskeletal dis-
orders (particularly symptomatic hip, knee and lumbar
osteoarthritis), uncorrected vision disturbance, vestibular
problems or any other health problem judged to inter-
fere with participation. Major depression, hallucinations
or other psychiatric disturbances will be exclusions.
Medical problems that might be worsened by donepezil
are exclusion criteria and include tachycardia, bradycar-
dia, arrhythmias, and peptic ulcer disease. Finally, use of
anticholinergics for parkinsonism, bladder antispas-
modics for urinary urgency or tricyclic antidepressants
for depression are contraindications as is concurrent use
of cholinesterase inhibitors for cognitive problems.
Intervention
See Fig. 1 for study design and summary of the assess-
ments. Subjects will receive the first study phase medica-
tions from the research pharmacy at the end of the
baseline testing. The research assistant will call subjects
weekly to ask about side effects or problems with the ex-
perimental medicines. They will also be asked about
falls. These contacts will be captured in case report
forms. If there are medical problems, the investigator
will call the subject or the subject will be brought into
clinic for evaluation. At 6 weeks, the subject will return
to the clinic for repeat testing with the measures
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captured at baseline (Fig. 1) and will undergo the SAI
testing. The subjects will then enter the 6-week washout
period. Although the subjects will be on no experimental
medications, they will continue to be called weekly to
inquire about side-effects, problems and falls. This is
partly done to keep the subject involved in the protocol,
as well as to collect data about falls. At the conclusion
of the 6 weeks, the subjects will return to the clinic for
repeat testing and to have medications dispensed for the
final 6-week phase of the protocol. The final 6-week
phase will be conducted exactly as was the first 6-week
phase with repeat testing at the end of the 6 weeks.
Cholinesterase inhibitors, such as donepezil, are stand-
ard of care for patients with PD who have cognitive im-
pairments [20]. We chose donepezil, an FDA approved
drug, because it is possible to create a placebo for the
donepezil tablet and it requires only once a day dosing.
It is recommended to start donepezil at 5 mg per day to
reduce adverse effects on the gastrointestinal system.
We will increase the dose to 10 mg/day after 3 weeks, if
tolerated, because that is the schedule used in our pilot
study and this titration was well tolerated [17]. Donepe-
zil has a half-life of 70 h and it requires approximately
15 days to reach steady state. The maximum effects on
cognitive measures occur within 3 weeks and loss of
effect requires more than 3 weeks and less than 6 weeks.
In our pilot study, there were more falls at 3 weeks and
5 mg/day of donepezil than at 6 weeks and 10 mg/day of
donepezil and 10 mg was more effective than 5 mg on
cognitive measures in PD [20]. Washout between phases
will be 6 weeks to minimize carry-over of effects.
Randomization and blinding
The Research Pharmacy at OHSU will be responsible for
purchasing study medication and creating blinded cap-
sules for each subject, maintaining and storing drug,
randomizing to maintain blinding, dispensing medica-
tion, and checking compliance by returned capsule
count.
Sample size
We estimated the sample sizes required to detect differ-
ential changes in the primary outcome measures be-
tween donepezil and placebo, assuming a crossover
design with 4 measurement time points (pre-post each
treatment interval, see Fig. 1). We informed sample size
and statistical power calculations based on preliminary
data from ten PD subjects enrolled in a blinded pilot
trial of donepezil vs. placebo who should be similar to
patients recruited for this proposal [19]. In that study,
Fig. 1 Study design and outcomes measures for each phase of the study
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sway velocity during donepezil treatment intervals de-
creased 2.35 units on average, while those on placebo in-
creased 5.38 units, with a common standard deviation
estimate of 9. We set power at 0.80 and level of signifi-
cance at 0.025 rather than 0.05 since there are two pri-
mary endpoints (to control for multiple comparisons).
Additionally, we assume no period effects will be ob-
served in the crossover design (that is, we do not an-
ticipate the order that patients receive treatment will
affect the outcomes). Calculations were conducted
using SAS v9.3 PROC POWER. Under these assump-
tions, a two-sided hypothesis test comparing sway vel-
ocity between donezepil and placebo would require
44 patients with complete outcome data. However, we
anticipate that some patients may drop out of the
study while on active treatment due to side-effects.
Thus, we intend to recruit and enroll 54 patients to
allow for up to 20 % drop out.
Assessment procedures
Subjects will have been off medications overnight (at
least 12 h washout). We will study the subjects when
they have been without drug overnight and are “off,” be-
cause we have shown that sway while standing still is
sensitive to dyskinesia when the subjects are “on” [21].
Further, some of the measures of standing and walking
are sensitive to levodopa [8] and we wish to examine the
effects of cholinergic manipulation without interference
from other drugs as much as possible.
Parkinsonism and general cognition will be docu-
mented with the MDS Unified Parkinson’s Disease Rat-
ing Scale (MDS-UPDRS) and the Montreal Cognitive
Assessment (MOCA) [22–24]. Subjects will also have
the Activities of Balance Confidence (ABC) [25] as a
measure of mobility limitation and the Parkinson’s Dis-
ease Questionnaire (PDQ-39) [26] as a measure of
health-related quality of life.
Primary outcome measures
Balance and gait kinematic performance will be recorded
by small, body-worn, inertial sensors, Opals by APDM.
The Opals consist of wireless, synchronized, triaxial ac-
celerometers and gyroscopes that record body motion at
128 Hz. The sensors will be applied bilaterally to the feet
and wrists as well as to the sternum and pelvis with Vel-
cro straps. Inertial data is wirelessly transmitted with
radio signals to a laptop that controls the protocol, al-
lows comment on individual trials, automatically calcu-
late some balance and gait metrics (Mobility Lab
software, www.apdm.com) and store raw data for further
analysis in Matlab.
To characterize postural sway, subjects will stand with
feet together with hands at their hips looking straight-
ahead at a fixed point in 4 different conditions: 1) eyes
opened, 2) eyes closed, 3) eyes open standing on foam
pad, 4) eyes closed standing on foam pad.
To characterize gait, subjects will be instructed to walk
at their comfortable pace down a 20-m long hallway,
turn around at each end and continue walking back and
forth. The 180° turns are automatically detected and an-
alyzed separately by Mobility Lab. Subjects will be
instructed to walk continuously at their natural pace
without talking or looking around. The 2-min walk will
provide the gait variability measurements.
Subjects will also perform three more balance and gait
trials with a cognitive, dual task paradigm, which consist
of counting backwards by 3’s. Subjects will first be pre-
sented with the task in sitting to make sure they under-
stand the instructions and record a baseline for 1 min.
Subsequently, subjects will perform the gait and balance
task with and without the dual task. The conditions re-
peated with dual task are standing with eyes opened on
firm surface and foam pad, as well as walking up and
down the hallway for 1 min. This will allow calculating
the dual-task costs on balance and walking [(dual-task
balance or gait performance minus single-task perform-
ance)/single task performance*100] as well as the cost of
performance of the dual task [(dual-task counting – single
task counting)/single task counting*100].
The primary measure of balance will be medial-lateral
postural sway range during quiet stance because: 1) it is
a predictor of future fall risk in subjects with PD, 2) it
changes significantly with exercise and 3) it predicts falls
in elderly subjects. In addition to medial-lateral sway
range, we will examine other measures that may reflect
changes in the postural motor control loop including:
total sway amplitude (measured as root mean square eg;
variability around the mean position) and jerkiness of
sway (measured by differentiating the acceleration values
of sway).
The primary measure of gait stability will be the
coefficient variability of stride duration (time) during a
2-min walk, as a surrogate for fall risk based on the lit-
erature [27]. Secondary gait outcome measures include
the following metrics and their coefficients of variability:
stride length, cadence, double support time, arm swing
amplitude, and mean trunk rotation. In addition, to de-
termine the interaction between attention and gait, we
will measure the change in lateral sway velocity and the
percent change in the variability of stride duration dur-
ing dual-tasks versus single tasks (ie; dual-task cost).
Secondary outcome measures
Attention Network Test (ANT)
Attention will be tested with the Attention Network test,
a 15-min, computerized test that examines the effects of
cues and targets within a single reaction time task to
provide a means of exploring the efficiency of the
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alerting, orienting, and executive control networks in-
volved in attention [28, 29].
Short-latency afferent inhibition (SAI)
SAI will be performed using a modified version of proto-
col described previously in literature [30, 31]. Surface
EMGs from the first dorsal interosseous muscle of the
most involved arm will record motor evoked potentials
(MEPs) from contralateral motor cortex transcranial
magnetic stimulation (TMS). We will measure SAI by
applying peripheral conditioning stimuli (electrical
stimulation of the median nerve at the wrist) followed
by central test stimuli (TMS of motor cortex). The in-
tensity of the conditioning peripheral stimuli will be set
at the value that evokes a twitch of the abductor pollicis
brevis muscle. TMS will be performed using a figure-
eight stimulating coil (external loop diameter = 9 cm)
powered from a Magstim 200 magnetic stimulator. We
will determine the resting motor threshold, which is de-
fined as the lowest stimulus intensity capable of eliciting
at least five MEPs with an amplitude of 50 μV or higher
in 10 consecutive trials. All subsequent trials to evoke
SAI will utilize an intensity of 120 % of resting motor
threshold. The peripheral conditioning stimuli will pre-
cede the cortical TMS at 6 different interstimulus inter-
vals (ISIs). We will determine the ISIs based on the
latency of the N20 component of the somatosensory
evoked potential (SSEP). To determine the N20 latency
of the median nerve, we will attach the active and refer-
ence electrodes 3 cm behind C3 and C4 respectively
(10–20 system). SAI will be randomly tested at 6 differ-
ent interstimulus intervals, with a minimum of 10 trials
at each interstimulus interval (from N20 in 1-ms incre-
ments until N20 + 5 ms), with 20 unconditioned (test)
stimuli also delivered randomly The peak-to-peak ampli-
tude of the conditioned motor evoked potentials at teach
interstimulus interval will be averaged and expressed as
a percentage of the averaged unconditioned motor
evoked potential (baseline). To reduce variability, the
conditioned responses will be combined across all inter-
stimulus intervals and be expressed as the percentage of
the unconditioned MEP as described by others [32, 33].
SAI requires no background EMG activity in the target
muscles so visual feedback of the background EMG will
be used.
Statistical analysis
Our statistical hypothesis is that the change in outcomes
between the week 0 and week 6 of the donepezil and
placebo phases will differ. Specifically, we will test the
hypotheses that augmenting cholinergic neurotransmis-
sion will improve sway and gait dual-tasking; attention
and SAI will be secondary endpoints. We anticipate the
clinical measures of PD severity (MDS-UDPRS), quality
of life (PDQ-39) and balance confidence (ABC) will be
less sensitive to drug effects but will examine them as
well.
A linear mixed model will be used to analyze out-
comes resulting from the crossover design with repeated
measures (pre/post for each treatment). The model will
include treatment effects, terms to assess period or car-
ryover effects (which are not anticipated, but will be
assessed and controlled for), and random effects for pa-
tients within treatments. The observations on each sub-
ject will be measures obtained at week 0 and 6 under
the different treatment conditions (donepezil/placebo).
Since in a typical experiment using repeated measures,
two measurements taken at adjacent times may be more
highly correlated than two measurements taken further
apart, we will use Bayesian Information Criterion (BIC)
to explore optimal covariance structure for the model.
The main focus of the study is to determine whether the
two treatments exhibit differential change over time, (i.e.
time by treatment interaction effect). In crossover de-
signs, missing data have much greater influence on the
analysis than they would in a parallel-groups design es-
pecially when missing data are not at random, such as
drop-outs due to the adverse effects of treatments. We
have conservatively estimated sample size required for
the trial assuming some patients drop out during the
donepezil phase. Our primary analytic strategy will em-
ploy an intent-to-treat (ITT) approach, whereby all ran-
domized patients are included in analyses, even if they
drop out before completing both treatment phases.
However, we will assess and report the impact of drop-
out by a) comparing demographic and clinical character-
istics of those that dropout to those that complete, and
b) re-analyzing outcomes models to only those that
complete the trial.
Discussion
We are particularly interested in determining whether
gait and balance are directly influenced by cholinergic
manipulation or whether changes in attention capacity
are primarily responsible for changes in balance and gait.
If, for example, we find that ability to balance and walk
when dual tasking is altered out of proportion to
changes during standing and walking without dual task-
ing, it would suggest that cholinergic systems mainly
contribute to attentional capacity required for balance
and gait. If Donepezil has opposite effects on specific at-
tention domains within the Attention Network Test, this
argument would be strengthened. Because of evidence
linking executive dysfunction with gait disorders, we ex-
pect that the executive attention may be affected out of
proportion to alerting and orienting aspects of attention,
although Posner and colleagues have linked alerting at-
tention to cholinergic function [28, 29].
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